Athens Research/Cambio - Excellence in Molecular Biology/0.25g/10-1529-02

价格
面议
货号:10-1529-02
浏览量:58
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Oligo Synthesis

Oligo Synthesis : CEPs

Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.

  • Catalogue
  • Description
  • Protocols
  • Notes
  • Applications & Benefits

N2-Amino-Modifier C6 dG

N2-Amino-Modifier C6 dG

Glen Research

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
10-1529-02N2-Amino-Modifier C6 dG0.25g£880.00£836.00Offer until : 31-Mar-2021Offer Code : GLEN55% off all Glen productsView OfferQuantityAdd to Order
10-1529-90N2-Amino-Modifier C6 dG100µmoles£384.00£364.80Offer until : 31-Mar-2021Offer Code : GLEN55% off all Glen productsView OfferQuantityAdd to Order
10-1529-95N2-Amino-Modifier C6 dG50µmoles£192.00£182.40Offer until : 31-Mar-2021Offer Code : GLEN55% off all Glen productsView OfferQuantityAdd to Order

N2-Amino-Modifier C6 dG

N2-Amino-Modifier C6 dG

Glen Research

N2-Amino-Modifier C6 dG

Structure

Catalog Number: 10-1529-xx

Description: N2-Amino-Modifier C6 dG

5"-Dimethoxytrityl-N2-[6-(trifluoroacetylamino)-hex-1-yl]-2"-deoxyGuanosine-3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
Formula: C48H60F3N8O8PM.W.: 965.01F.W.: 428.38

Diluent: Anhydrous Acetonitrile
Coupling: N2-Amino-Modifier C6 dG reacts in a manner identical to normal phosphoramidites. To prevent side reactions, synthesize using acetyl-protected dC. See Deprotection for further details.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer. The TFA protecting group is removed during standard ammonium hydroxide deprotection. A minor side reaction during ammonia deprotection can lead to irreversibly capping 2-5% of the amine. This could be significant if multiple additions of the modifier are made. To prevent the reaction, synthesize using acetyl-protected dC and deprotect in 30% ammonia/40% methylamine 1:1 (AMA) at 65°C for 10 minutes.
Storage: Refrigerated storage, maximum of 2-8°C, dry

Stability in Solution: 2-3 days

SEQUENCE MODIFIERS

Sequence Modifiers are designed for use in automated synthesis. The carboxy-dT is hydrolyzed during deprotection and can be coupled directly to a molecule containing a primary amino group by a standard peptide coupling or via the intermediate N-hydroxysuccinimide (NHS) ester. Amino-Modifier dA, Amino-Modifier dC, Amino-Modifier dG and both Amino-Modifier dT products can be added in place of a dA, dC, dG and dT residue, respectively, during oligonucleotide synthesis. Corresponding Amino-Modifier supports can replace their respective deoxynucleoside supports. After deprotection, the primary amine on the C6 analogues is separated from the oligonucleotide by a spacer arm with a total of 7 -10 atoms and can be labelled or attached to an enzyme. The C2 analogue is more suitable for the attachment of molecules designed to react with the oligonucleotide.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

N2-Amino-Modifier C6 dG

N2-Amino-Modifier C6 dG

Glen Research

Material Safety Data Sheet

N2-amino-dG.pdf: N2-Amino-Modifier C6 dG - A new dG Amino-Modifier with improved hybridization characteristics
Glen Report 22.1: New Product - A dG Amino-Modifier with improved hybridization characteristics

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

N2-Amino-Modifier C6 dG

N2-Amino-Modifier C6 dG

Glen Research

Technical Notes

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

N2-Amino-Modifier C6 dG

N2-Amino-Modifier C6 dG

Glen Research

DILUTION/COUPLING DATA

The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link formore detailed usage informationwith the various synthesizers.

ABI 392/394
Cat.No.PackSizeGrams/Pack0.1M Dil.(mL)LV40LV20040nm0.2µm1µm10µm
Approximate Number of Additions
10-1529-020.25grams.25grams2.597343.827.3819.9114.63.65
10-1529-90100µmoles.097grams120127.55.4541
10-1529-9550µmoles.048grams.53.3321.25.91.67.17
Expedite
Cat.No.PackSizeGrams/PackDilution(mL)Molarity50nm0.2µm1µm15µm
Approximate Number of Additions
10-1529-020.25grams.25grams3.87.077144.3832.274.44
10-1529-90100µmoles.097grams1.5.0723.614.7510.731.48
10-1529-9550µmoles.048grams.75.078.65.383.91.54
Beckman
Cat.No.PackSizeGrams/PackDilution(mL)Molarity30nm200nm1000nm
Approximate Number of Additions
10-1529-020.25grams.25grams3.87.0772.645.3833
10-1529-90100µmoles.097grams1.5.0725.215.7511.45
10-1529-9550µmoles.048grams.75.0710.26.384.64

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.